The year 2019 witnessed a catastrophe that shook the entire world. With COVID-19, everything came to a halt. The pandemic forced the industry to disrupt at a pace never seen or known before.
One of the many aspects that saw a huge shift was how stakeholders across the life sciences value chain exchanged valuable information with each other. At the Indegene Digital Summit, industry experts Gergana Zlateva – VP, Value and Access Oncology at Pfizer, Brian Clark - Head US market access rare diseases at Chiesi USA, Jim Ballenger – Principal at Ballenger Rx Consulting, and Jack Mycka – VP, Enterprise Medical Solutions and Emerging Biotech, talked about how things have changed and evolved in the communications between pharmaceutical manufacturers, marketers, and payers in the US over the last few years, especially post-COVID, and what the future looks like.
Key takeaways from the panel discussion:
The panelists also discussed and debated the role of the Inflation Reduction Act in payer communications. Overall, the session brings a wealth of information about how payer communications have changed over the course of time and what to expect in the near future. The speakers quoted multiple examples from their own experiences.